Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.

von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS.

Eur Neurol. 2015;73(3-4):238-46. doi: 10.1159/000377675. Epub 2015 Mar 25.

PMID:
25824054
2.

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.

Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076. eCollection 2015 Jun.

3.

B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity.

Lehmann-Horn K, Sagan SA, Bernard CC, Sobel RA, Zamvil SS.

Ann Neurol. 2015 May;77(5):902-8. doi: 10.1002/ana.24387. Epub 2015 Mar 28.

PMID:
25712734
4.

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Zamvil SS, Slavin AJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62. doi: 10.1212/NXI.0000000000000062. eCollection 2015 Feb. Review.

5.

Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE.

Shetty A, Gupta SG, Varrin-Doyer M, Weber MS, Prod'homme T, Molnarfi N, Ji N, Nelson PA, Patarroyo JC, Schulze-Topphoff U, Fogal SE, Forsthuber T, Sobel RA, Bernard CC, Slavin AJ, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 14;1(2):e22. doi: 10.1212/NXI.0000000000000022. eCollection 2014 Aug.

6.

MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS.

Varrin-Doyer M, Shetty A, Spencer CM, Schulze-Topphoff U, Weber MS, Bernard CC, Forsthuber T, Cree BA, Slavin AJ, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 14;1(2):e20. doi: 10.1212/NXI.0000000000000020. eCollection 2014 Aug.

7.

Precision medicine in chronic disease management: The multiple sclerosis BioScreen.

Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL.

Ann Neurol. 2014 Nov;76(5):633-42. doi: 10.1002/ana.24282. Epub 2014 Oct 14. Review.

PMID:
25263997
8.

Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.

Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U.

Exp Neurol. 2014 Dec;262 Pt A:66-71. doi: 10.1016/j.expneurol.2014.04.002. Epub 2014 Apr 13. Review.

9.

Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.

Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS.

J Neuroinflammation. 2014 Feb 6;11:29. doi: 10.1186/1742-2094-11-29.

10.

MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies.

Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil SS.

J Exp Med. 2013 Dec 16;210(13):2921-37. doi: 10.1084/jem.20130699. Epub 2013 Dec 9.

11.

Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS.

JAMA Neurol. 2013 Oct;70(10):1315-24. Review.

12.

Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity.

Schulze-Topphoff U, Casazza S, Varrin-Doyer M, Pekarek K, Sobel RA, Hauser SL, Oksenberg JR, Zamvil SS, Baranzini SE.

J Exp Med. 2013 Jul 1;210(7):1301-9.

13.

The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis.

Cravens PD, Kieseier BC, Hussain R, Herndon E, Arellano B, Ben LH, Timmons BC, Castro-Rojas C, Hartung HP, Hemmer B, Weber MS, Zamvil SS, Stüve O.

J Neuroinflammation. 2013 May 24;10:67. doi: 10.1186/1742-2094-10-67.

14.

Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity.

Hertzenberg D, Lehmann-Horn K, Kinzel S, Husterer V, Cravens PD, Kieseier BC, Hemmer B, Brück W, Zamvil SS, Stüve O, Weber MS.

Eur J Immunol. 2013 Aug;43(8):2078-88. doi: 10.1002/eji.201343338. Epub 2013 Jun 3.

15.

Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter.

Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS.

Ann Neurol. 2012 Jul;72(1):53-64. doi: 10.1002/ana.23651. Epub 2012 Jul 17.

16.

Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.

Brück W, Zamvil SS.

Expert Rev Clin Pharmacol. 2012 May;5(3):245-56. doi: 10.1586/ecp.12.12. Review.

PMID:
22697588
17.

K+ channel alterations in the progression of experimental autoimmune encephalomyelitis.

Jukkola PI, Lovett-Racke AE, Zamvil SS, Gu C.

Neurobiol Dis. 2012 Aug;47(2):280-93. doi: 10.1016/j.nbd.2012.04.012. Epub 2012 Apr 24.

18.

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil SS.

PLoS One. 2012;7(3):e33797. doi: 10.1371/journal.pone.0033797. Epub 2012 Mar 30.

19.

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.

Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team.

Neurology. 2012 Apr 10;78(15):1171-8. doi: 10.1212/WNL.0b013e31824f7fdd. Epub 2012 Mar 28.

20.

Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica.

Steinman L, Zamvil SS.

Ann Neurol. 2012 Mar;71(3):287-8. doi: 10.1002/ana.23538. No abstract available.

PMID:
22451198
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk